Rybelsus Medicaid Coverage by State Tier: 2026 Guide

What Is Rybelsus and Why Does Coverage Tier Matter?

Rybelsus is the first oral GLP-1 receptor agonist approved by the FDA for adults with type 2 diabetes. The FDA granted approval in September 2019 (NDA 213051) based on the PIONEER clinical program [1]. Unlike injectable semaglutide (Ozempic, Wegovy), it is taken as a single tablet on an empty stomach each morning with no more than 4 oz of water.

Clinical Evidence That Drives Coverage Decisions

Payers base formulary placement largely on clinical outcomes. In the PIONEER 7 trial (N=504), flexibly dosed oral semaglutide reduced HbA1c by 1.2 percentage points versus a 0.02-percentage-point reduction with placebo over 52 weeks [2]. The American Diabetes Association (ADA) 2024 Standards of Care recommend GLP-1 receptor agonists as preferred add-on agents when cardiovascular disease is present or when additional glucose lowering beyond metformin is needed [3].

How Formulary Tiers Work in Medicaid

State Medicaid programs use preferred drug lists (PDLs). A drug on the preferred tier (Tier 1 or Tier 2) generally requires no PA or only simple PA, while a non-preferred or specialty placement triggers step-therapy, meaning the patient must fail one or two older agents first. The Centers for Medicare and Medicaid Services (CMS) allows states to manage their own PDLs within federal best-price and rebate rules [4].

State-by-State Rybelsus Medicaid Tier Overview

Coverage rules shift at each annual PDL cycle. The table below reflects published state PDL documents available as of Q1 2026. Always confirm with your state Medicaid pharmacy program or prescribing provider before submitting a claim.

Preferred / No Prior Authorization States

Several states have placed Rybelsus on the preferred tier with no PA required or with a simple quantity limit only:

• California (Medi-Cal): Preferred; quantity limit of 30 tablets per 30 days; no PA required for patients with documented type 2 diabetes diagnosis.
• New York (NY Medicaid): Preferred; PA required only for doses above 7 mg without an HbA1c >8% on file.
• Washington (Apple Health): Preferred with attestation of type 2 diabetes; no step therapy.
• Colorado: Preferred; PA required for the 14 mg dose only.
• Minnesota: Preferred; DUR board approved unrestricted preferred status effective January 2025.

In these states, a patient with a valid type 2 diabetes diagnosis and a prescription from a licensed provider will typically pay $0 to $3 at the pharmacy counter under standard Medicaid cost-sharing rules [4].

Step-Therapy / Non-Preferred States

In step-therapy states, Rybelsus sits on the non-preferred tier and requires documented failure of at least one preferred agent (most commonly metformin, then a sulfonylurea or SGLT-2 inhibitor) before PA is approved:

• Texas (Texas Medicaid): Non-preferred; requires documented metformin trial (minimum 90 days at maximally tolerated dose) plus HbA1c >7.5%.
• Florida (FL Medicaid): Non-preferred specialty; requires failure of metformin AND one sulfonylurea; PA valid for 12 months.
• Ohio (Ohio Medicaid): Non-preferred; step therapy through metformin, then one additional oral agent; PA renewed annually.
• Georgia (GA Medicaid): Non-preferred; requires HbA1c >7% on two agents plus cardiologist or endocrinologist attestation for cardiovascular high-risk patients.
• Pennsylvania (PA Medicaid): Non-preferred; step-therapy through metformin; PA granted if metformin is contraindicated due to renal impairment (eGFR <30 mL/min/1.73 m²).

Step-therapy hurdles can be overridden with a medical exception request when metformin is contraindicated (e.g., severe renal impairment, lactic acidosis risk) or when a specialist documents clinical urgency. The Endocrine Society position statement supports exception pathways for patients with documented cardiovascular risk [5].

Medicaid Expansion States vs. Non-Expansion States

Under the Affordable Care Act, 41 states plus DC had expanded Medicaid as of January 2026. Expansion broadens eligibility to adults earning up to 138% FPL. Non-expansion states have narrower eligibility, meaning some low-income adults who qualify on income do not qualify categorically [4]. This coverage gap disproportionately affects patients who could benefit most from GLP-1 therapy given the association between lower socioeconomic status and higher type 2 diabetes prevalence documented in CDC surveillance data [6].

How to Get Rybelsus Cheaper: Programs Beyond Medicaid

Even if your state's Medicaid program denies coverage or places Rybelsus in a non-preferred tier, several pathways can reduce cost substantially.

Novo Nordisk Patient Assistance Program (PAP)

Novo Nordisk's Patient Assistance Program provides Rybelsus at no cost to uninsured or underinsured patients with household income at or below 400% of the federal poverty level. Applications are submitted through the Novo Nordisk Patient Assistance portal. The FDA requires manufacturers to maintain PAP programs as a condition of Medicaid rebate agreements under the Medicaid Drug Rebate Program (MDRP) [7].

Rybelsus Savings Card (Commercially Insured Patients)

For patients with commercial insurance (not Medicaid or Medicare), Novo Nordisk offers a savings card that reduces the monthly cost to as low as $10 for eligible patients. This copay assistance is not available for government-program beneficiaries due to federal anti-kickback statute restrictions [8]. Patients enrolled in Medicare Part D are excluded by law.

GoodRx, Mark Cuban Cost Plus, and Pharmacy Discount Programs

GoodRx and similar discount platforms negotiate cash prices with pharmacy benefit managers. As of early 2026, cash-pay prices for a 30-tablet supply of Rybelsus 7 mg range from approximately $820 to $940 at major retail chains without a coupon, and from approximately $650 to $780 with a GoodRx-type coupon. These prices are lower than the WAC (wholesale acquisition cost) of approximately $990 per month but are still substantial. Mark Cuban's Cost Plus Drugs does not currently list Rybelsus because Novo Nordisk has not opted into that formulary.

340B Drug Pricing Program

Federally Qualified Health Centers (FQHCs), rural health clinics, and certain safety-net hospitals participate in the 340B program, which requires manufacturers to provide outpatient drugs at significantly reduced prices. A patient receiving care at a 340B-covered entity may access Rybelsus at 340B ceiling price, which can be 25% to 50% below WAC. The Health Resources and Services Administration (HRSA) oversees 340B eligibility [9].

Telehealth Prescribers and Compounding: What to Know

Some telehealth platforms advertise "compounded semaglutide" at lower prices. The FDA issued multiple guidance documents in 2024 warning that compounded oral semaglutide has not been evaluated for bioavailability, safety, or efficacy and is not FDA-approved [10]. Rybelsus uses a specific absorption enhancer (SNAC, sodium N-(8-(2-hydroxybenzoyl) amino) caprylate) that is patented and not easily replicated. Patients seeking cost savings should use manufacturer programs or 340B entities rather than compounded alternatives.

Prior Authorization: Step-by-Step Approval Process

Getting a PA approved is manageable when the submission is complete the first time.

What Documentation to Gather

Most state Medicaid PA forms for Rybelsus require:

1. Current HbA1c value (date and lab source)
2. Documentation of prior drug trials (medication name, dose, duration, outcome)
3. Diagnosis code (ICD-10 E11.xx for type 2 diabetes)
4. Prescriber NPI and DEA number
5. For cardiovascular-risk exceptions: documentation of ASCVD, heart failure (NYHA class), or CKD stage

The ADA notes that HbA1c reduction remains the primary outcome measure for PA clinical criteria, consistent with Standards of Care Section 9 [3].

Timeline and Appeals

Most state Medicaid programs must respond to a PA request within 3 business days for non-urgent cases and 24 hours for urgent cases under CMS regulations [4]. If the PA is denied, the prescriber can file a first-level appeal within 30 days, followed by a state fair hearing if that appeal fails. Peer-to-peer review calls with the plan's medical director resolve many denials within a single 15-minute conversation.

Writing a Successful Medical Exception Letter

A strong exception letter cites the specific PDL criteria, demonstrates each criterion is met, and references published guidelines. For example: citing the ADA recommendation that GLP-1 RAs are preferred agents in patients with established cardiovascular disease [3] alongside the PIONEER 6 trial result, where oral semaglutide reduced the rate of major adverse cardiovascular events by 21% relative to placebo (hazard ratio 0.79; 95% CI 0.57 to 1.11) [11], makes a clinically grounded case even if the primary endpoint was non-inferiority.

Rybelsus and Medicare Part D

Medicare Part D covers Rybelsus for type 2 diabetes when the patient meets the plan formulary criteria. The Inflation Reduction Act (IRA) 2022 capped out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year starting January 2025, which meaningfully reduces annual exposure for patients taking specialty-tier medications [12]. Low-Income Subsidy (LIS / Extra Help) beneficiaries pay $0 to $11.20 per fill depending on subsidy level. Patients who qualify for both Medicare and Medicaid (dual eligibles) are automatically enrolled in LIS and pay the lowest cost-sharing tier.

Can I Use HSA or FSA for Rybelsus?

Yes. Rybelsus is a prescription drug and qualifies as an eligible medical expense under IRS Publication 502, which governs both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) [13]. You pay out of pocket at the pharmacy, then submit the pharmacy receipt and prescription label through your plan administrator for reimbursement, or use your HSA/FSA debit card directly at the point of sale.

The IRS does not impose a diagnosis requirement for HSA/FSA eligibility of prescription drugs. As long as the drug is prescribed by a licensed provider for a medical condition, the expense qualifies. Patients using an HSA receive a triple tax advantage: pre-tax contributions, tax-free growth, and tax-free withdrawals for qualified expenses [13].

HSA/FSA funds can also cover related costs: the prescriber visit, lab work (HbA1c, metabolic panel), and diabetes education programs certified by the ADA [14].

Rybelsus Dosing, Titration, and Medicaid Quantity Limits

Understanding standard dosing helps anticipate quantity-limit PA triggers.

Approved Titration Schedule

The FDA-approved titration for Rybelsus is [1]:

• Weeks 1 to 4: 3 mg once daily (tolerability dose; not expected to produce glycemic effect)
• Week 5 onward: 7 mg once daily
• If additional glycemic control is needed after at least 4 weeks at 7 mg: increase to 14 mg once daily

Most state Medicaid PDLs impose a quantity limit of 30 tablets per 30 days at any single dose. PA requests for dose escalation (particularly from 7 mg to 14 mg) typically require a repeat HbA1c showing inadequate control (<1% reduction or HbA1c still above 7.5%).

Renal and Hepatic Considerations

No dose adjustment is required for mild to moderate renal impairment. The FDA label notes that exposure increases in severe renal impairment; clinical monitoring is recommended [1]. In patients with eGFR <30 mL/min/1.73 m², metformin is contraindicated, which strengthens the medical exception argument for bypassing metformin step therapy in those patients [3].

Clinical Outcomes That Support Rybelsus Coverage

Payers and pharmacy benefit managers evaluate coverage against clinical evidence. The PIONEER program across 10 trials provides the broadest evidence base for oral semaglutide.

PIONEER 1 and PIONEER 2 Key Results

In PIONEER 1 (N=703), oral semaglutide 14 mg reduced HbA1c by 1.5 percentage points from a mean baseline of 7.9% at 26 weeks compared with a 0.1-percentage-point reduction with placebo (P<0.001) [15]. In PIONEER 2 (N=822), oral semaglutide 14 mg produced a 1.3-percentage-point HbA1c reduction versus 0.9 percentage points with empagliflozin 25 mg at 52 weeks [16]. These data support placement on preferred formulary tiers relative to SGLT-2 inhibitors where glycemic control is the primary need.

PIONEER 6 Cardiovascular Safety

PIONEER 6 (N=3,183) was a cardiovascular outcomes trial designed to demonstrate non-inferiority of oral semaglutide versus placebo in patients with high cardiovascular risk. The trial met its primary non-inferiority endpoint, and the hazard ratio for MACE (major adverse cardiovascular events) was 0.79 (95% CI 0.57 to 1.11), consistent with cardiovascular safety [11]. Payers increasingly cite PIONEER 6 when placing GLP-1 agonists on preferred tiers for patients with documented ASCVD.

Weight Effects in Diabetes Patients

Although Rybelsus is not FDA-approved for weight loss (that indication belongs to Wegovy/semaglutide 2.4 mg subcutaneous), PIONEER 1 showed a 2.3-kg mean weight reduction with the 14-mg dose versus 1.4 kg with placebo at 26 weeks [15]. State Medicaid programs generally do not cover Rybelsus for weight loss alone; the type 2 diabetes indication must be documented for coverage.

Medicaid Rebates and Why They Affect Your Access

Under the Medicaid Drug Rebate Program, manufacturers pay rebates to CMS and states to participate in Medicaid. Basic rebates equal 23.1% of the average manufacturer price (AMP) for single-source brand drugs, with additional inflation-based rebates when prices rise faster than CPI-U [7]. These rebates reduce the net cost to state programs and are a reason states are generally willing to cover brand GLP-1 agents despite high list prices. The AMP-based system means that patients on Medicaid pay cost-sharing on a gross price that the state partially recoups on the back end.

State Medicaid Contact Resources

When you need to confirm current PDL status, these primary contacts are most reliable:

• CMS Medicaid Drug Rebate Program data: cms.gov/medicaid/prescription-drugs
• State PDL databases: Each state Medicaid agency publishes its PDL online; search "[state name] Medicaid preferred drug list 2026"
• HRSA 340B database: hrsa.gov/opa to find covered entities near you
• Novo Nordisk PAP: 1-866-310-7549 or novonordisk-us.com/patients/patient-assistance